Ad
related to: fshd
Search results
Sanofi strikes $1bn deal with Fulcrum for muscular dystrophy drug
Pharmaceutical Technology via Yahoo Finance· 4 weeks agoFulcrum Therapeutics has signed a $1bn exclusive licence deal with Sanofi to develop and...
Fulcrum Therapeutics Inc (FULC) Reports Q3 2023 Financial Results and Business Highlights
GuruFocus.com via Yahoo Finance· 7 months agoFulcrum Therapeutics Inc (NASDAQ:FULC) reported a net loss of $24.0 million for Q3 2023, compared to...
Sanofi gambles $80M on Fulcrum’s muscular dystrophy drug
BioPharma Dive via Yahoo Finance· 4 weeks agoThe deal gives the pharma partial rights to a medicine GSK once developed for heart disease but...
FSHD Society Western Pa. chapter gets ready to 'Drum & Roll'
Tribune-Review, Greensburg, Pa. via Yahoo News· 2 years agoOct. 15—Members of the FSHD Society Western Pennsylvania chapter are getting ready to rock 'n roll for the second annual Drum & Roll to Cure FSHD event. Set for 1 to 3 p.m. Nov. 5 at the Andrew ...
Sanofi In-Licenses Preclinical Genetic Disease Candidate From An Unknown Biotech
Benzinga via Yahoo Finance· 2 years agoFrench pharma major Sanofi SA (NASDAQ: SNY) entered into a collaboration and licensing agreement...
Fulcrum Therapeutics Inc (FULC) Reports Financial Results for Q4 and Full Year 2023
GuruFocus.com via Yahoo Finance· 3 months agoCash Position: Increased to $236.2 million as of December 31, 2023, from $202.9 million the previous...
Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
GuruFocus.com via Yahoo Finance· 4 weeks agoNet Loss: Reported a net loss of $26.9 million for Q1 2024, an increase from a net loss of $24.8...
Biotech Stock Roundup: NVAX, FULC Up on Deals With SNY, Updates From MRNA, BMY
Zacks via Yahoo Finance· 3 weeks agoAs the earnings come to an end in the ongoing reporting cycle, the focus shifts to pipeline and...
Goldman Sachs Predicts up to 108% Rally for These 2 ‘Strong Buy’ Stocks
TipRanks via Yahoo Finance· 2 weeks agoGiven the S&P 500‘s recent surge beyond 5,300, surpassing some experts’ year-end targets, is it...
Fulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 3 months agoFulcrum Therapeutics, Inc. (NASDAQ:FULC) Q4 2023 Earnings Call Transcript February 27, 2024 Fulcrum...
